Wnt Decoy Receptor (sLRP6E1E2) Induces Antifibrotic Effect Via Inhibition of Wnt Signaling in Keloid Scars
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jung-Sun | - |
dc.contributor.author | Lee, Won Jai | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.date.accessioned | 2021-08-03T12:36:42Z | - |
dc.date.available | 2021-08-03T12:36:42Z | - |
dc.date.created | 2021-07-26 | - |
dc.date.issued | 2013-05-15 | - |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/48148 | - |
dc.description.abstract | Keloid scars are pathologic proliferations of the dermal skin layer resulting from excessive collagen deposition. The aberrant activation of the Wnt pathway signaling plays a critical role in keloid scars. In this study, we evaluated the therapeutic potential of a soluble Wnt receptor decoy in treatment of keloid scars. Therefore, we designed a Wnt antagonist sLRP6E1E2, and generated a replication-incompetent adenovirus (Ad), dE1-k35/sLRP6E1E2. We showed that γ-galactosidase expression confirmed the efficient transduction of dE1-K35/lacZ into human dermal fibroblasts. In addition, dE1-k35/ sLRP6E1E2 prevented Wnt-mediated stabilization of cytoplasmic γ-catenin and decreased Wnt/γ-catenin signaling. dE1-k35/ sLRP6E1E2 also inhibited Wnt-induced TGF-b up-regulation as well as Smad2/3 signaling pathway. Consistent with these data, the expression of ECM proteins was significantly decreased in keloid spheroids transduced with dE1-k35/sLRP6E1E2. These results suggest that the antifibrotic effect of sLRP6E1E2-expressing adenovirus may have therapeutic effects on keloids. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.title | Wnt Decoy Receptor (sLRP6E1E2) Induces Antifibrotic Effect Via Inhibition of Wnt Signaling in Keloid Scars | - |
dc.type | Conference | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.wosid | 000319858400131 | - |
dc.identifier.bibliographicCitation | 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), pp.S53 | - |
dc.relation.isPartOf | 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT) | - |
dc.relation.isPartOf | MOLECULAR THERAPY | - |
dc.citation.title | 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT) | - |
dc.citation.startPage | S53 | - |
dc.citation.endPage | S53 | - |
dc.citation.conferencePlace | US | - |
dc.citation.conferencePlace | Salt Lake City, UT | - |
dc.citation.conferenceDate | 2013-05-15 | - |
dc.type.rims | CONF | - |
dc.description.journalClass | 1 | - |
dc.identifier.url | https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)34465-3#relatedArticles | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.